Decreasing Frequency of Osteonecrosis of the Jaw in Cancer and Myeloma Patients Treated with Bisphosphonates: The Experience of the Oncology Network of Piedmont and Aosta Valley (North-Western Italy)

Table 2

Duration and dose of bisphosphonate treatment at the ONJ onset time.

Drug	No.	Median duration and range (months)	Median dose and range (mg)
Zoledronate only	127	20.7 (1.8–74.5)	72 (12–212)
Pamidronate only	16	38.6 (5.5–102.7)	2085 (360–4080)
Pamidronate/zoledronate	43	56.0 (6.5–203.1)	PAM 1080 (90–4680)/ZOL 88 (16–216)
Zoledronate/pamidronate	5	28.3 (10.8–38.3)	ZOL 48 (40–108)/PAM 270 (90–1260)